View in EDS

Phase Ib and dose-expansion study of GSK3326595, a PRMT5 inhibitor as monotherapy and in combination with pembrolizumab in patients with advanced cancers.

Saved in:
Bibliographic Details
Title: Phase Ib and dose-expansion study of GSK3326595, a PRMT5 inhibitor as monotherapy and in combination with pembrolizumab in patients with advanced cancers.
Authors: Gounder, M.M.1,2 (AUTHOR), Martin-Romano, P.3 (AUTHOR), Italiano, A.4,5 (AUTHOR), Siu, L.L.6 (AUTHOR), Cassier, P.A.7 (AUTHOR), Falchook, G.S.8 (AUTHOR), Lossos, I.S.9 (AUTHOR), Rasco, D.W.10 (AUTHOR), Hilton, J.F.11 (AUTHOR), McKean, M.A.12 (AUTHOR), Opdam, F.L.13 (AUTHOR), Strauss, J.14 (AUTHOR), De Jonge, M.15 (AUTHOR), Vermaat, J.S.P.16 (AUTHOR), Crossman, T.17 (AUTHOR), Zajac, M.17 (AUTHOR), Tarkar, A.18 (AUTHOR), Gonzalez Carreras, F.19 (AUTHOR), Kremer, B.E.1,18 (AUTHOR) brandon.e.kremer@gsk.com, Barbash, O.18 (AUTHOR)
Source: Annals of Oncology. Dec2025, Vol. 36 Issue 12, p1480-1491. 12p.
Database: Academic Search Ultimate
Description
ISSN:09237534
DOI:10.1016/j.annonc.2025.08.3757